Related Experiment Video
Updated: May 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
[Cirrhotic cardiomyopathy: a specific entity]
A Brondex1, F Arlès, A-S Lipovac
1Service de cardiologie et pathologie vasculaire, hôpital d'instruction des armées Legouest, Metz, France. abrondex@hotmail.com
Insights
Cirrhosis can cause cirrhotic cardiomyopathy, a heart condition with significant hemodynamic changes. Awareness is key, as stress can unmask latent heart failure in advanced liver disease patients.
Area of Science:
- Cardiology
- Hepatology
- Internal Medicine
Context:
- Cirrhosis, the advanced stage of chronic liver disease, presents complex challenges.
- It is frequently associated with significant hemodynamic alterations, including hyperdynamic circulation.
- These alterations contribute to a spectrum of cardiac abnormalities known as cirrhotic cardiomyopathy.
Purpose:
- To describe the characteristics and clinical implications of cirrhotic cardiomyopathy.
- To highlight the multifactorial pathogenesis of this cardiac condition.
- To emphasize the importance of recognizing cirrhotic cardiomyopathy in clinical practice.
Summary:
- Cirrhotic cardiomyopathy involves structural, functional, electrophysiological, and biological heart abnormalities.
- The condition is often clinically silent due to reduced left ventricular afterload from peripheral vasodilation.
- Stressors like surgery, shunts, or beta-blocker therapy can unmask latent heart failure or contribute to hepatorenal syndrome.
Impact:
- Early recognition of cirrhotic cardiomyopathy is crucial for managing patients with advanced cirrhosis.
- Understanding this syndrome can improve patient outcomes and guide management strategies.
- Further research is needed to establish diagnostic criteria and refine treatment recommendations.
Abstract:
Cirrhosis is a frequent and severe condition, which is the late stage of numerous chronic liver diseases. It is associated with major hemodynamic alterations characteristic of hyperdynamic circulation and with a series of structural, functional, electrophysiological and biological heart abnormalities termed cirrhotic cardiomyopathy. The pathogenesis of this syndrome is multifactorial. It is usually clinically latent or mild, likely because the peripheral vasodilatation significantly reduces the left ventricle afterload. However, sudden changes of hemodynamic state (vascular filling, surgical or transjugular intrahepatic porto-systemic shunts, peritoneo-venous shunts and orthotopic liver transplantation) or myocardial contractility (introduction of beta-blocker therapy) can unmask its presence, and sometimes convert latent to overt heart failure. Cirrhotic cardiomyopathy may also contribute to the pathogenesis of hepatorenal syndrome. This entity has been described recently, and its diagnostic criteria are still under debate. To date, current management recommendations are empirical, nonspecific measures. Recognition of cirrhotic cardiomyopathy depends on a high level of awareness for the presence of this syndrome, particularly in patients with advanced cirrhosis who undergo significant surgical, pharmacological or physiological stresses.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cirrhosis I: Introduction
Cardiomyopathy V: Interprofessional Care
